A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 143

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 143
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 209
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 994
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3134
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis. | LitMetric

AI Article Synopsis

  • New oral anticoagulants (NOACs) are approved for treating nonvalvular atrial fibrillation (AF) and were compared with warfarin in this study.
  • The analysis included six randomized controlled trials involving 13,850 patients, focusing on stroke, systemic embolism, and bleeding risks.
  • Results showed that NOACs significantly reduced the risks of stroke, systemic embolism, and intracranial hemorrhage while having comparable safety profiles to warfarin for patients with AF and valvular heart disease.

Article Abstract

Introduction: New oral anticoagulants (NOACs) are approved for use in nonvalvular atrial fibrillation (AF).

Objectives: This study aimed to evaluate the efficacy and safety of NOACs compared with warfarin in AF and valvular heart disease (VHD).

Methods: We identified randomized controlled trials (RCTs) and post-hoc analyses comparing NOACs and warfarin in AF and VHD, including biological and mechanical heart valves (MHV). Through systematic review and meta-analysis, with the aid of the "Rev Man" program 5.3, the primary effectiveness endpoints were stroke and systemic embolism (SE). The primary safety outcome was major bleeding, and the secondary outcome included intracranial hemorrhage. Data were analyzed using risk ratios (RRs) and 95% confidence intervals (CIs), and heterogeneity was assessed using the I statistic.

Results: Six RCTs were included, involving 13,850 patients with AF and VHD. NOACs significantly reduced the risk of stroke/SE (RR 0.78; 95% CI 0.66-0.91; P = 0.002) and intracranial hemorrhage (RR 0.51; 95% CI 0.33-0.79; P = 0.003) and lowered the risk of major bleeding (RR 0.77; 95% CI 0.58-1.02; P = 0.07) compared with warfarin.

Conclusions: The efficacy and safety of NOACs as thromboprophylaxis for AF and VHD are similar to those of warfarin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544604PMC
http://dx.doi.org/10.1007/s40268-019-0274-zDOI Listing

Publication Analysis

Top Keywords

oral anticoagulants
8
atrial fibrillation
8
valvular heart
8
heart disease
8
systematic review
8
review meta-analysis
8
efficacy safety
8
safety noacs
8
major bleeding
8
intracranial hemorrhage
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!